Dextera Surgical Inc. (NASDAQ:DXTR) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition
On October5, 2017, Dextera Surgical Inc. issued a corporate updatefor its fiscal quarter ended September 30, 2017. A copy of Dextera’s press release, dated October 5, 2017, is attached hereto as Exhibit99.1.
The information set forth under this Item 2.02, including the exhibit attached hereto, shall not be deemed “filed” for purposes ofSection18 of the Securities and Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
|
Item 2.02 |
Financial Statements and Exhibits. |
|
99.1 |
Press release dated October 5, 2017, containing Dextera Surgical Inc.’s corporate update for the fiscal quarter ended September 30, 2017. |
DEXTERA SURGICAL INC ExhibitEX-99.1 2 ex_96317.htm EXHIBIT 99.1 ex_96317.htm Exhibit 99.1 DEXTERA SURGICAL PROVIDES CORPORATE UPDATE — Preliminary Fiscal 2018 First Quarter Revenue – — Update on Strategic Partnership — — Conference Call at 8:30 a.m. ET Today — REDWOOD CITY,…To view the full exhibit click here
About Dextera Surgical Inc. (NASDAQ:DXTR)
Dextera Surgical Inc., formerly Cardica, Inc., designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons. Its MicroCutter 5/80 is a commercially available cartridge-based microcutter device with approximately five millimeter shaft diameter, over 80 degrees of articulation, and an approximately 30 millimeter staple line cleared for specified indications for use in the United States, and in the European Union (EU) for a range of indications for use. It designs, manufactures and markets automated anastomotic systems used by surgeons to perform anastomoses during on- or off-pump coronary artery bypass graft procedures and these products include the C-Port xA system, the C-Port Flex A system and the PAS-Port Proximal Anastomosis System.